Blocking excess TNFa by its antagonists including TNF receptor 2-IgG1 fusion protein (Etanercept) and anti-TNFα monoclonal antibodies (Infliximab and Adalimumab) has been validated as an effective treatment for RA [1], [3]–[4], although not all patients respond well to the treatment (25% to 38% of Etanercept patients; 21% to 42% of Infliximab patients). The gene discussed is TNF; the disease is rheumatoid arthritis.